قالب وردپرس درنا توس
Home / Business / Johnson & Johnson is starting trials with COVID-19 after eliciting an immune response in primates

Johnson & Johnson is starting trials with COVID-19 after eliciting an immune response in primates



Johnson & Johnson JNJ,
-0.19%
He said on Thursday that her main vaccine candidate protected herself in preclinical studies from infection with SARS-CoV-2, the virus that causes COVID-19. The vaccine provided a robust immune response, as demonstrated by “neutralizing antibodies” that successfully prevent subsequent infection and provide complete or almost complete protection against viral viruses in non-human primates. Based on strong data, the first phase 1

/ 2a clinical study with a human candidate for the Ad26.COV2.S vaccine was initiated in humans in the United States and Belgium. Discussions are currently underway with partners to begin a pivotal phase 3 clinical trial with a single dose of vaccine versus placebo in September, pending preliminary data from phase 1 and 2 trials and regulatory approval, Johnson & Johnson said.


Source link